Patents by Inventor Stephen R. Petteway

Stephen R. Petteway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant plasmin for opthalmic indications
    Patent number: 8231869
    Abstract: Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: July 31, 2012
    Assignee: Grifols Therapeutics Inc.
    Inventors: Philip Scuderi, Jr., Vikram Arora, Jennifer A. Hunt, Valery Novokhatny, Stephen R. Petteway, Jr.
  • RECOMBINANTLY MODIFIED PLASMIN
    Publication number: 20100047228
    Abstract: Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
    Type: Application
    Filed: October 18, 2006
    Publication date: February 25, 2010
    Inventors: Philip Scuderi, JR., Vikram Arora, Jennifer A. Hunt, Valery Novokhatny, Stephen R. Petteway, JR.
  • Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
    Patent number: 5562905
    Abstract: A chemically synthesized 15 amino acid peptide designated peptide 1-69, which has the sequence of amino acids numbers 308 to 322 (RIQRGPGRAFVTIGK) of the human immunodeficiency virus-1 (HIV-1) IIIB env-coded protein, was used to immunize animals. Peptide 1-69 elicited in immunized animals antibodies that block HIV proliferation and block HIV-induced cell fusion in cell culture.
    Type: Grant
    Filed: March 20, 1989
    Date of Patent: October 8, 1996
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: William R. Kenealy, Stephen R. Petteway, Paul J. Durda
  • Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
    Patent number: 5026635
    Abstract: The invention relates to stable mammalian cells lines having integrated in their genome two heterologous DNA sequences, a first DNA sequence which expresses a trans-acting regulatory protein, and a second DNA sequence which expresses a desired protein, said second DNA sequence being linked to a target DNA regulatory control sequence which is responsive to the expressed trans-acting regulatory protein.
    Type: Grant
    Filed: April 26, 1990
    Date of Patent: June 25, 1991
    Assignee: Du Pont Merck Pharmaceutical
    Inventors: Blair Q. Ferguson, Lee T. Bacheler, Stephen R. Petteway, Russell H. Neubauer